STAT3
Signal transducer and activator of transcription 3
As of the edition of 20 October 2026, STAT3 (signal transducer and activator of transcription 3, UniProt P40763) has 8 drugs tested at it and 10 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P40763
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 6
- Disease areas
- Cancer; Blood and lymph; Digestive system; Immune system; Lungs and airways; Hormones; Skin and connective tissue; Heart and blood vessels
- Registered trials of its drugs
- 43
Drugs at this target
| Status | Count |
|---|---|
| Active | 3 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Danvatirsen | Stopped | Phase 2 | none listed |
| C-188-9 | Active | Phase 2 | none listed |
| OPB-111077 | Active | Phase 2 | none listed |
| OPB 31121 | Went quiet | Phase 2 | none listed |
| OPB-51602 | Stopped | Phase 1 | none listed |
| WP 1066 | Active | Phase 2 | none listed |
| SC-43 | Stopped | Phase 2 | none listed |
| KT-333 | Status not established | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Flamingo Therapeutics | Route A |
| Otsuka | Route A |
| Acerta Pharma | Route A |
The other 7 companies at STAT3
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at STAT3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.